HALOPERIDOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Haloperidol, and when can generic versions of Haloperidol launch?
Haloperidol is a drug marketed by Alpharma, Lannett Co Inc, Morton Grove, Pharm Assoc, Rubicon, SCS, Teva, Teva Pharms, Abraxis Pharm, Baxter Hlthcare Corp, Epic Pharma Llc, Fosun Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Marsam Pharms Llc, Mylan Labs Ltd, Sagent Pharms, Smith And Nephew, Solopak, Teva Pharms Usa, Watson Labs, Actavis Group, Aiping Pharm Inc, Aurobindo Pharma Ltd, Chartwell Rx, Duramed Pharms Barr, Innogenix, Lederle, Mankind Pharma, MSN, Mylan, Par Pharm, Purepac Pharm, Quantum Pharmics, Royce Labs, Sciegen Pharms Inc, Strides Pharma, Upsher Smith Labs, Zydus Pharms Usa, Hospira, Meitheal, Sandoz, Somerset Theraps Llc, Zydus Pharms, and Actavis Mid Atlantic. and is included in one hundred and seven NDAs.
The generic ingredient in HALOPERIDOL is haloperidol decanoate. There are twenty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the haloperidol decanoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Haloperidol
A generic version of HALOPERIDOL was approved as haloperidol decanoate by FRESENIUS KABI USA on December 19th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HALOPERIDOL?
- What are the global sales for HALOPERIDOL?
- What is Average Wholesale Price for HALOPERIDOL?
Summary for HALOPERIDOL
| US Patents: | 0 |
| Applicants: | 46 |
| NDAs: | 107 |
| Finished Product Suppliers / Packagers: | 32 |
| Raw Ingredient (Bulk) Api Vendors: | 122 |
| Clinical Trials: | 219 |
| Patent Applications: | 3,833 |
| Drug Prices: | Drug price information for HALOPERIDOL |
| Drug Sales Revenues: | Drug sales revenues for HALOPERIDOL |
| What excipients (inactive ingredients) are in HALOPERIDOL? | HALOPERIDOL excipients list |
| DailyMed Link: | HALOPERIDOL at DailyMed |
See drug prices for HALOPERIDOL
Recent Clinical Trials for HALOPERIDOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | Phase 4 |
| Christian Hassager | Phase 3 |
| Qilu Pharmaceutical Co., Ltd. | Phase 3 |
Pharmacology for HALOPERIDOL
| Drug Class | Typical Antipsychotic |
Medical Subject Heading (MeSH) Categories for HALOPERIDOL
Anatomical Therapeutic Chemical (ATC) Classes for HALOPERIDOL
US Patents and Regulatory Information for HALOPERIDOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma | HALOPERIDOL | haloperidol | TABLET;ORAL | 216918-003 | Apr 11, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Royce Labs | HALOPERIDOL | haloperidol | TABLET;ORAL | 071724-001 | Dec 24, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurobindo Pharma Ltd | HALOPERIDOL | haloperidol | TABLET;ORAL | 218789-002 | Apr 19, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Actavis Group | HALOPERIDOL | haloperidol | TABLET;ORAL | 200854-002 | Jul 1, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sandoz | HALOPERIDOL DECANOATE | haloperidol decanoate | INJECTABLE;INJECTION | 076463-002 | Jun 24, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mylan | HALOPERIDOL | haloperidol | TABLET;ORAL | 070278-002 | Jul 16, 2009 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Strides Pharma | HALOPERIDOL | haloperidol | TABLET;ORAL | 071235-002 | Nov 3, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
